Form 4: Neurocrine Biosciences Officer Delaet Reports Stock Transactions

Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, reports the acquisition and disposal of common stock and restricted stock units (RSUs) on January 31, 2025, and February 3, 2025, under a pre-arranged trading plan.

Summary

• Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, filed a Form 4 detailing changes in beneficial ownership.
• On January 31, 2025, Delaet acquired 801 shares of common stock through the vesting of restricted stock units (RSUs) and disposed of 422 shares at a weighted average price of $153.0491 per share.
• On February 3, 2025, Delaet acquired 1,179 shares of common stock through the vesting of RSUs and disposed of 623 shares at a price of $149.29 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 13, 2022.
• Following these transactions, Delaet directly owns 3,442 shares of Neurocrine Biosciences common stock and no derivative securities.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock transactions by an officer under a pre-existing trading plan. There is no indication of positive or negative sentiment towards the company's prospects.

Positives

• The transactions are part of a pre-arranged 10b5-1 trading plan, suggesting they were planned well in advance and not based on immediate insider information.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the trading activities of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Monitoring insider transactions is a standard practice in corporate governance, ensuring transparency and preventing illegal insider trading.
• Companies like Amgen, Biogen, and Gilead Sciences also have officers who regularly file Form 4s, reflecting the common practice of stock-based compensation and trading plans in the biotechnology industry.

Stakeholder Impact

• The reported transactions may have a minor impact on shareholders by increasing the float of available shares.

Key Dates

Keywords

Form 4, Neurocrine Biosciences, NBIX, Insider Trading, Stock Transactions, Beneficial Ownership, Restricted Stock Units, Rule 10b5-1, Ingrid Delaet, Chief Regulatory Officer